Term
|
Definition
| Monoamine neuro transmittreer. inhibits prolactin secretion. acts on D1 and D2 receptors. high levels promote schizophrenia and low levels promote parkinsonism. increases libido |
|
|
Term
|
Definition
| Amino acid based neurotransmitter. inhibitory actions in CNS works on chloride channels |
|
|
Term
|
Definition
| Amino acid based neurotransmitter. Excitatory in CNS works on sodium channels |
|
|
Term
|
Definition
| Amino acid based neurotransmitter. increases affinity of glutamate for its receptor. inhibitory in spinal cord prevents over stimulation. |
|
|
Term
|
Definition
| lipid based CNS neurotransmitter. reduces anxiety, elevates mood, stimulates appetite, invovled in motor coordination. inperiphery stimulates fat accumulation. helps with embryo implantaion in uterus |
|
|
Term
|
Definition
| inhibits tyrosine hydroxylase (the enzyme that converts tyrosine to DOPA). used in the treatment of a pheochromcytoma |
|
|
Term
|
Definition
| inhibits L-aromatic amino acid decarboxylase(DOPA decarboxylase) preventing the formation of Dopamine from DOPA. Used in conjunction with L-DOPA to treat Parkinson's symptoms. Carbidopa does not cross the BBB but L-DOPA does. |
|
|
Term
|
Definition
| inhibits COMT preventing the metabolism of L-DOPA to 3-O-MD in the periphery. also used in treatment of Parkison's disease. |
|
|
Term
|
Definition
| inhibits dopamine-beta-hydoxylase and prevents conversion of dopamin to NE. used in treatment of alcoholism. this drug chelates copper and effects acetyl dehydrogenase thereby increasing the feeling of a hangover after ingesting small amounts of alcohol. |
|
|
Term
|
Definition
| prevents uptake of NE and dopamine into synaptic vesicles in nerve varicosities. less NE in vesicle leads to less release in cleft. used for treament of HTN and psychosis. also damages vesicles creating a chemical sympathectomy by also decreasing levels of E and Serotonin. |
|
|
Term
|
Definition
| drug that is converted to NE by DOPA decarboxylase. used in treatment of familial dysautonomia (deficiency in dopamine-beta-hydroxylase) |
|
|
Term
|
Definition
| precursor of NE that can cross BBB. used in treatment of HTN. alpha-methylnorepinephrine is a false neurotransmittter that causes vasonconstriction in periphery but its action on alpha 2 receptor in RVLM in brain reducing impulses to release NE and false neurotransmitter decreasing BP. |
|
|
Term
|
Definition
| contains proteases that degrade the proteins involved in exocytosis of NE containing synaptic vesicles. degrade synaptobrevin, syntaxin, and SNAP-25 |
|
|
Term
|
Definition
| initial NE release followed by blocking of exocytosis and inhibition of NE release. used in critical cardiac care in unresponsive arrythmias. |
|
|
Term
|
Definition
| beta 1 and 2 receptor agonist that cannot be taken up by amine pump transporter in nerver terminal. |
|
|
Term
|
Definition
| blocks amine pump transporter and inhibits reuptake of NE, E, and dopamine by presynaptic neuron. results in more NE in cleft |
|
|
Term
|
Definition
| drug that is taken up by amine pump transporter and displaces NE in synaptic vesicles causing NE to be displaced into the clefts. does not require an AP to release NE. is an indirect sympathomimetic |
|
|
Term
|
Definition
| sympathomimetic acting on alpha 1 and 2 and beta 1 and 2 receptors |
|
|
Term
|
Definition
| sympathomimetic that acts on alpha 1 and 2 and beta 1 receptors. |
|
|
Term
|
Definition
| sympathomimetic that acts on alpha 1 receptor only. |
|
|
Term
|
Definition
| sympathomimetic that acts only on alpha 1 receptor. |
|
|
Term
|
Definition
| Sympathomimetic that acts on alpha 2 receptor. |
|
|
Term
|
Definition
| Sympathomimetic that acts on alpha 2 receptor |
|
|
Term
|
Definition
| sympathomimetic that acts on beta 1 receptor primarily and at high doses stimulates beta 2 and alpha 1 receptors |
|
|
Term
|
Definition
| direct acting beta 2 adrenergic agonist |
|
|
Term
|
Definition
| direct acting beta 2 adrenergic agonist |
|
|
Term
|
Definition
| direct acting beta 2 adrenergic agonist |
|
|
Term
|
Definition
| direct acting beta 2 adrenergic agonist |
|
|
Term
|
Definition
| direct acting beta 2 adrenergic agonist. has a longer duration of action |
|
|
Term
|
Definition
| direct acting beta 2 adrenergic agonist. has a longer duration of action |
|
|
Term
| TCA e.g. Desipramine and Amitryptyline |
|
Definition
| inhibit neuronal uptake of NE. Tx: depression |
|
|
Term
|
Definition
| MAO-a and b inhibitor. used for treatment of depression and panic disorders. |
|
|
Term
|
Definition
| MAO-a and b inhibitor. used for treatment of depression and panic disorders. |
|
|
Term
|
Definition
| MAO-b inhibitor. used in treatment of parkison's to reduce L-DOPA degradation |
|
|
Term
|
Definition
| anatgonist the blocks alpha 1 and 2 receptors |
|
|
Term
|
Definition
| anatgonist the blocks alpha 1 and 2 receptors. long lasting effects |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| nonselective beta 1 and 2 anatgonist with low lipid solubility |
|
|
Term
|
Definition
| nonselective beta 1 and 2 anatgonist with low lipid solubility |
|
|
Term
|
Definition
| nonselective beta 1 and 2 anatgonist with low-moderate lipid solubility |
|
|
Term
|
Definition
| nonselective beta 1 and 2 anatgonist with high lipid solubility |
|
|
Term
|
Definition
| nonselective beta 1 and 2 anatgonist with high lipid solubility |
|
|
Term
|
Definition
| beta 1 antagonist with low lipid solubility |
|
|
Term
|
Definition
| beta 1 antagonist with low lipid solubility |
|
|
Term
|
Definition
| beta 1 antagonist with moderate lipid solubility |
|
|
Term
|
Definition
| beta 1 and 2 and alpha 1 antagonistwith moderate lipid solubility |
|
|
Term
|
Definition
| beta 1 and 2 and alpha 1 antagonist with low lipid solubility |
|
|
Term
|
Definition
| not approved beta 2 antagonist |
|
|
Term
|
Definition
| histamine receptor antagonist |
|
|
Term
| alpha 1 receptor actions at post junction |
|
Definition
vasoconstriction of blood vessels
decreased GI motility and tone
Stimulation of glycogenlysis
Contraction of sphincter muscle in GI and bladder, and radial muscle in eye |
|
|
Term
| alpha 2 receptor actions at post junction |
|
Definition
vasoconstriction of blood vessels
Hypotension RVLM
Decreased GI motility and tone
Inhibition of insulin release pancreas
Fat cell lipolysis
Platelet aggregation |
|
|
Term
| beta 1 post junctional response |
|
Definition
cardiac stimulation of heart
Decreased GI motility and tone
Adipose tissue fatty acid mobilization
Increased Renin release kidney |
|
|
Term
| beta 2 post junctional response |
|
Definition
Dilation of arteries and veins, Decreased GI motility and tone, Increased insulin secretion pancreas, Glycogenolysis and gluconeogenesis liver and muscle, Increased glucagon secretion
Relaxation of bronchial smooth muscle and bladder detrusser and pregnant uterus |
|
|
Term
| pre-junctional adrenergic alpha 2 response |
|
Definition
inhibition of NE release from adrenergic nerves
Inhibition of Ach release from parasympathetic nerve
Inhibition of serotonin
inhibition of dopamine release in brain |
|
|
Term
| pre-junctional adrenergic beta 2 response |
|
Definition
| increase NE release from adrenergic nerves |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| post junctional D1 response |
|
Definition
| vascular relaxation in renal and mesenteric blood vessels, Natriuresis and diuresis in kidney, Stimulation of parathyroid hormone release |
|
|
Term
| post junctional D2 response |
|
Definition
| inhibition of prolactin release |
|
|
Term
| Pre junctional D2 response |
|
Definition
inhibition of NE release from adrenergic nerves
Inhibition of Dopamine release from from dopaminergic nerve and CNS |
|
|
Term
|
Definition
| direct alpha 1 and beta 2 agonist also has indirect actions |
|
|
Term
|
Definition
| direct alpha 1 agonist also has indirect actions |
|
|
Term
|
Definition
| D1 and D2 antagonist used for psychogenic disorders |
|
|
